← Back to Clinical Trials
Recruiting NCT05817734

NCT05817734 Human Phenotype Project Study Protocol

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05817734
Status Recruiting
Phase
Sponsor Weizmann Institute of Science
Condition Adult Disease
Study Type OBSERVATIONAL
Enrollment 30,000 participants
Start Date 2018-10-01
Primary Completion 2045-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30,000 participants in total. It began in 2018-10-01 with a primary completion date of 2045-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective study aimed at recruiting 30,000 individuals, aged 40-70 years old, and following them longitudinally for 25 years with repeated measurements. The basic follow-up frame will include a visit to the Clinical Test Center (CTC) every two years and a phone interview every other year (on uneven years). Sample collection and biobanking will be performed every two years and online questionnaires will be filled out on an annual basis. The primary goals are to study the variation observed across different individuals in disease susceptibility, clinical phenotypes, and therapeutic responses. The study aims at studying the complex interplay and relative contribution of different omics, physiological characteristics and lifestyle on disease pathogenesis and progression and to evaluate how these effects are mediated.

Eligibility Criteria

Inclusion Criteria: * Ages 18+, males and females. Exclusion Criteria: * Pregnancy. * Mentally disabled or in general legally non-competent. * Prisoner or soldier. Soldiers: mandatory service only * Active cancer * Fertility Treatments (current) * Hepatitis ( B, C), chronic or acute * HIV * Liver cirrhosis * Dialysis * Unstable medical conditions

Contact & Investigator

Central Contact

Eran Segal, Prof.

✉ Eran.Segal@weizmann.ac.il

📞 972-8-9343266

Frequently Asked Questions

Who can join the NCT05817734 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Adult Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05817734 currently recruiting?

Yes, NCT05817734 is actively recruiting participants. Contact the research team at Eran.Segal@weizmann.ac.il for enrollment information.

Where is the NCT05817734 trial being conducted?

This trial is being conducted at Rehovot, Israel.

Who is sponsoring the NCT05817734 clinical trial?

NCT05817734 is sponsored by Weizmann Institute of Science. The trial plans to enroll 30,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology